Press release
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to
About this update from Illumina, Inc.
[{"type":"text","content":"Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies\nIllumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq™ Dx System \nSAN DIEGO, May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer. Illumina tumor profiling and in vitro diagnostic (IVD) solutions will be on display at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.\n\n \n \n \n \n \n \n\n \n\"Access to tumor profiling is essential to deliver on the promise of precision cancer care,\" said Everett Cunningham, chief commercial officer of Illumina. \"With our growing portfolio of distributable clinical solutions, we are unlocking the next new standard of care for clinicians and their patients. With TSO Comprehensive and Pillar oncoReveal CDx, more labs can perform tumor profiling in-house, allowing oncologists to rapidly understand the genomic drivers of disease, and match their patients to the best possible therapies.\" \nIllumina TruSight™ (TSO) Comprehensive is the first and only FDA-approved test offering a distributable comprehensive genomic profiling IVD kit with pan-cancer CDx claims, evaluating both DNA and RNA. This enables clinicians to rapidly match cancer patients with targeted therapies using comprehensive tumor profiling. Illumina customers across the US -- in community oncology care practices, regional hospitals and health systems, and academic medical centers -- are integrating TSO Comprehensive into their clinical practice. This month, UofL Health – UofL Hospital became the first Illumina customer to begin offering the test to patients.\n\"We are excited to bring TSO Comprehensive to our patient and provider community. Access to an in-house comprehensive tumor profiling solution will allow our care teams to deliver faster precision therapy decisions for our patients,\" said Mustafa Al-Kawaaz, MD, assistant p...